Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 12/20 | 0.38 |
| ▸ | DCUN1D1 | Q96GG9 | 6/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | UBE2M | P61081 | 1/20 | 0.31 |
| ▸ | DCUN1D2 | Q6PH85 | 1/20 | 0.31 |
| ▸ | DCUN1D3 | Q8IWE4 | 1/20 | 0.31 |
| ▸ | DCUN1D4 | Q92564 | 1/20 | 0.31 |
| ▸ | DCUN1D5 | Q9BTE7 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12410900 | 0.92 | ADORA1 (0.43) | ADORA1DCUN1D1DRD2HTR2AHRH1 | |
| SCHEMBL7999964 | 0.85 | ADORA1 (0.43) | ADORA1RETSLC6A3 | |
| SCHEMBL12376557 | 0.81 | ADORA1 (0.51) | ADORA1SLC6A3 | |
| SCHEMBL12409163 | 0.80 | ADORA1 (0.51) | ADORA1DCUN1D1SLC6A3 | |
| SCHEMBL12376551 | 0.79 | NPC1 (0.39) | ADORA1RETSLC6A3 | |
| SCHEMBL12376494 | 0.79 | NPC1 (0.42) | ADORA1DCUN1D1DRD2HTR2AHRH1 | |
| SCHEMBL12376570 | 0.78 | ADORA1 (0.38) | ADORA1SLC6A3 | |
| SCHEMBL12376539 | 0.78 | ADORA1 (0.46) | ADORA1RETSLC6A3 | |
| SCHEMBL12535544 | 0.78 | ADORA1 (0.49) | ADORA1SLC6A3 | |
| SCHEMBL12376553 | 0.75 | ADORA1 (0.40) | ADORA1DCUN1D1RETSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426602-B2 | Heteroaryl-substituted dicyanopyridines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-23 | — | — | US | disclosed |
| US-20110207698-A1 | HETEROARYL-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207698-A1 | HETEROARYL-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE | QDPR, TNNI3, SDHA | ADORA1 3151/4885DCUN1D1 1655/4885DRD2 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.